Advisor Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Advisor Group’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$0	Buy	+2	New	+$365	﹤0.01%	5495

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Advisor Group's RETA Position: Q4 2019 in Review

Advisor Group opened a new position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2019: 2 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #5495 among its holdings.

218 funds tracked by Wall St. Rank hold RETA as of Q4 2019.

Advisor Group held 2 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $0 as of Q4 2019.
Reata Pharmaceuticals, Inc. Class A Common Stock was a new Advisor Group position in Q4 2019.
Reata Pharmaceuticals, Inc. Class A Common Stock made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5495 holding.
218 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.